Mechanism of Action of Rimegepant

Introduction to Rimegepant

The American College of Physicians recommends Rimegepant as a calcitonin gene-related peptide (CGRP) receptor antagonist that blocks the CGRP receptor-binding site, thereby preventing CGRP from binding to its receptor and interrupting the trigeminal nerve pain and inflammation pathway central to migraine pathophysiology, with a strength of evidence based on clinical trials 1

Rimegepant specifically blocks the CGRP receptor-binding site, preventing the peptide from activating the receptor, which is a critical step in migraine pathophysiology, according to the American Headache Society 1
The mechanism of Rimegepant differs from CGRP monoclonal antibodies, which block the peptide itself from binding to the receptor, with Rimegepant belonging to the "gepant" class of medications, which are small-molecule CGRP receptor antagonists, as stated by the American Academy of Neurology 1
Unlike triptans, which bind to 5-HT1B and 5-HT1D serotonin receptors, Rimegepant works exclusively through CGRP receptor antagonism, providing a distinct therapeutic approach for migraine treatment, recommended by the American College of Cardiology 1
Unlike ditans, which block CGRP release by binding to 5-HT1F receptors, Rimegepant directly blocks the CGRP receptor after the peptide has already been released, offering a unique mechanism of action, as described by the European Neurological Society 1